US 12,102,705 B2
Peptides having inhibitory activity on muscarinic receptor M3
Francesca Mancini, Nettuno (IT); Isabel Devesa Giner, Elche (ES); Antonio Ferrer Montiel, Alicante (ES); Gregorio Fernandez Ballester, Murcia (ES); Giorgina Mangano, Rome (IT); and Cristina Bartella, Rome (IT)
Assigned to AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO—A.C.R.A.F. S.p.A., Rome (IT)
Appl. No. 15/734,033
Filed by AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO—A.C.R.A.F. S.p.A., Rome (IT)
PCT Filed Jun. 11, 2019, PCT No. PCT/EP2019/065223
§ 371(c)(1), (2) Date Dec. 1, 2020,
PCT Pub. No. WO2019/238686, PCT Pub. Date Dec. 19, 2019.
Claims priority of application No. 18177587 (EP), filed on Jun. 13, 2018.
Prior Publication US 2022/0142898 A1, May 12, 2022
Int. Cl. A61K 8/64 (2006.01); A61K 38/00 (2006.01); A61Q 15/00 (2006.01); C07K 5/117 (2006.01); C07K 7/06 (2006.01); C07K 7/08 (2006.01)
CPC A61K 8/64 (2013.01) [A61Q 15/00 (2013.01); C07K 5/1024 (2013.01); C07K 7/06 (2013.01); C07K 7/08 (2013.01); A61K 38/00 (2013.01)] 18 Claims
 
1. A peptide or a derivative or salt thereof having a length equal to or lower than 6 amino acids and that is different from peptide ALWMRL, wherein:
said peptide or a derivative or salt thereof contains any one of sequences ID nos. 1 to 5, or
said peptide or a derivative or salt thereof contains a sequence having at least 70% sequence identity with any one of the sequences nos. ID 1 to 5, and
wherein in said derivative, an N-and/or C- terminal is chemically modified or protected with an organic compound.